Blueshift Asset Management, LLC Arcus Biosciences, Inc. Transaction History

Blueshift Asset Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$17.23 - $37.73 $143,474 - $314,177	-8,327 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$28.92 - $41.83 $240,816 - $348,318	8,327 New	8,327 $263,000
Q4 2021 Feb 11, 2022	SELL	$31.38 - $48.47 $370,786 - $572,721	-11,816 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$26.93 - $37.68 $357,818 - $500,654	-13,287 Reduced 52.93%	11,816 $412,000
Q2 2021 Aug 13, 2021	BUY	$22.75 - $35.77 $571,093 - $897,934	25,103 New	25,103 $689,000
Q4 2020 Feb 12, 2021	SELL	$17.0 - $32.36 $331,347 - $630,728	-19,491 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$17.14 - $25.47 $118,814 - $176,558	-6,932 Reduced 26.23%	19,491 $334,000
Q2 2020 Aug 13, 2020	BUY	$13.97 - $36.56 $369,129 - $966,024	26,423 New	26,423 $654,000

200

51.5M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $950M
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Blueshift Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Blueshift Asset Management, LLC with notifications on news.